EP0988282A2 - Neue pentaerythritderivate, deren herstellung und verwendung sowie intermediate zur synthese derselben - Google Patents

Neue pentaerythritderivate, deren herstellung und verwendung sowie intermediate zur synthese derselben

Info

Publication number
EP0988282A2
EP0988282A2 EP98936180A EP98936180A EP0988282A2 EP 0988282 A2 EP0988282 A2 EP 0988282A2 EP 98936180 A EP98936180 A EP 98936180A EP 98936180 A EP98936180 A EP 98936180A EP 0988282 A2 EP0988282 A2 EP 0988282A2
Authority
EP
European Patent Office
Prior art keywords
formula
compounds
compound according
propyl
cor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98936180A
Other languages
German (de)
English (en)
French (fr)
Inventor
Gerd König
Ulrich Hess
Anne-Katrin Windeck
Holger Brosig
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Puren Pharma GmbH and Co KG
Original Assignee
Isis Pharma GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Pharma GmbH filed Critical Isis Pharma GmbH
Publication of EP0988282A2 publication Critical patent/EP0988282A2/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms

Definitions

  • the invention presented here relates to new pentaerythritol derivatives, their preparation and use and intermediates for the synthesis thereof, which can be used in particular as pharmaceuticals
  • GTN glycerol nitrate
  • PETN pentaerythritol tetranitrate
  • Isosorbid-5-monontrate (DE-OS-22 21 080, DE-OS-27 51 934, DE-OS-30 28 873, DE-PS-29 03 927, DE-OS-31 02 947 DE- OS-31 24 410, EP-A1-045 076 EP-A1-057 847, EP-A1-059 664, EP-A1-064 194, EP-A1-067 964, EP-A1-143 507, US-PS -3 886 186, U.S. Patent 4,065,488, U.S. 4,417,065, U.S. 4,431,829), Isosorbide Diitrate (ISDN) (L.
  • ISDN Isosorbide Diitrate
  • angina pecto ⁇ s or ischemic heart disease is primarily peroral, parenteral, subimgual or transdermal application in the form of tablets, coated tablets, solutions, Cover sprays or plasters (DD-A5-293 492.
  • nitrate tolerance can be observed, ie the decrease in the nitrate effect at high doses or when long-acting nitrates are applied , Dizziness, nausea, weakness of skin reddening and the risk of a greater drop in blood pressure with reflex tachycardia (Mutschier drug effects,ticianliche Verlagsgesellschaft mbH, Stuttgart, 1991).
  • PETN as an active ingredient has a number of outstanding properties, which make it a preferred use of this compound as a pharmaceutical over other organic drugs
  • This active ingredient has a number of outstanding properties, which make it a preferred use of this compound as a pharmaceutical over other organic drugs
  • Lipophilic organic nitrates are, as a result of a faster metabolic breakdown to less effective or ineffective biotransformation products, generally only effective for a short time (Bonn, "Pharmacokinetics of Organic Nitrates" in "Pentaerythyltetranitrate", Dr Dietrich Steinkopff Verlag, Darmstadt, 1995)
  • the object of the invention is to provide new compounds derived from pentaerythritol with pharmacologically advantageous effects.
  • the object of the invention is achieved by the new compounds of the formulas (I) and (III), (O 2 NOCH 2 ) m C (CH 2 OH) n (CH 2 C0R 1 ) 0 (C0R 1 ) p , (I) ( ⁇ 2NOCH 2 ) m C (CH 2 OH) n (CH 2 COR) o (COR 3 ) p (III) wo ⁇ n R 'is a group of the formula (II), or R 3 is a group of the formula (IV),
  • R 2 is n-butyl, n-pentyl, n-hexyl, benzyl, 2-phenylethyl, 3-phenylpropyl, 3-phthal ⁇ m ⁇ dylpropyl or 5-ethoxycarbonyibutyl
  • the starting products for the synthesis of the compounds of the formulas (I) and (III) are pentaerythritol or its nitric acid ester, namely pentaerythritol mono- (PEMN), pentaerythritol ti- di (PEDN), pentaerythryl tri- (PETnN) and pentaerythryl tetranitrate (PETN), which in turn are known per se (Simecek, Coll Czech Chem Comm 27 (1962), 363, Camp et al, J Am Chem Soc 77 (1955), 751) are synthetically accessible in good yields.
  • PEMN pentaerythritol mono-
  • PEDN pentaerythritol ti- di
  • PETnN pentaerythryl tri-
  • PETN pentaerythryl tetranitrate
  • the compounds PEMN, PEDN and PETnN are obtained by complete or partial oxidation of existing hydroxymethyl groups converted into the corresponding Tn-, di- or monocarboxylic acids, from which the corresponding derivatives carrying both nitroxy, hydroxyl and carboxy functions are optionally obtained by partial hydrazolysis of the corresponding nitrate function
  • R 2 has the meaning given in the formula (I) and R 4 represents H or a suitable leaving group which can be obtained in good yields from the compounds of the formula (IV 1) according to the reaction scheme given in FIG. 1
  • R 2 has the meaning already given in formula (I) and R 4 is H, C to C 6 -alkanoyl, salicyloyl or acetylsalicyloyl, are an independent embodiment of the invention.
  • the compounds in which R 2 is n-butyl, n-Pentyl, n-hexyl, benzyl, 2-phenylethyl, 3-phenylpropyl, 3-phthal ⁇ m ⁇ dylpropyl or 5-ethoxycarbonylbutyl is further preferred are compounds in which R 4 is salicyloyl or acetylsalicyloyl and compounds in which R 2 is n-butyl, n-pentyl , n-hexyl, benzyl, 2-phenylethyl, 3-phenylpropyl, 3-phthal ⁇ m ⁇ dylpropyl or 5-ethoxycarbonylbutyl and R 4 are salicyloyl or acetylsal
  • a particular embodiment of the present invention are the compounds of the formula (X)
  • R 8 to R 10 have the meaning given in the formula (IX) and R 11 is N0 2 , and the compounds of the formula (XI) derived therefrom,
  • R 12 is additionally a C to C 6 alkyl, in particular methyl, ethyl or n-propyl
  • X represents a group capable of forming anions which need not be present if the function COR 10 has the ability to form internal salts.
  • the compounds of the formula (XII) are particularly preferred
  • the end product is obtained either as free acid or base, base or acid addition salt or betaine, each of which is within the scope of the invention.
  • Acidic, basic, neutral or mixed salts and hydrates can be obtained respective salts can be converted into the free acid or base in a manner known per se using appropriate means or by ion exchange.
  • the free acids or bases obtained can form salts with organic or inorganic bases or acids.
  • Bases such as these are mainly used in the preparation of base addition salts which form suitable therapeutically compatible salts.
  • bases are, for example, hydroxides or hydrides of the alkali and alkaline earth metals, ammonia and ames.
  • acids which are suitable therapeutically contractual salts
  • Such acids are, for example, hydrogen halide, sulfonic, phosphoric, nitric and perchloric acid, furthermore aliphatic, acyclic, aromatic, heterocyclic carbonic or sulfonic acids such as formic, acetic, propionic, amber, glycolic, lactic, Apple, who, lemon, glucon, sugar, glucuron, ascorbic, maleic, hydroxymalein, pyruvic, phenylacetic, benzoic, p-aminobenzoic, anthranilic, p-hydroxybezoic, salicyl -, Acetylsa cyl- p-aminosa cyl, embon, methanesulfone, ethanesulfone, hydroxyethanesulfone, ethylenesulfone, halobenzenesulfonic, tolu
  • Salts of the acids or bases can be formed and separated from solutions, and then the free acid or base can be obtained from a new salt solution in a purer state Because of the relationship between the new compounds in their free form and their salts, the salts are within the scope of the invention.
  • Some of the new compounds may be present as optical isomers or racemates (or at least, depending on the choice of starting materials and process) contain two asymmetric carbon atoms, they can exist as a mixture of isomers (racemate mixture).
  • the isomer mixtures (racemate mixtures) obtained can be separated into two stereoisomeric (diastereomeric) pure racemates with the aid of chromatography or fractional crystallization.
  • racemates obtained can be separated by methods known per se as by re-installation from an optically active solvent, by using microorganisms, by reaction with optically active agents to form compounds which can be separated, by separation on the basis of the different solubilities ⁇ er diastereoisomers
  • Suitable optically active agents are the L and D forms of Wem, D ⁇ -o-tolylwe ⁇ n, apple, almond, gluconic, sugar, glucuronic, camphorsuifo ⁇ , quinine or binaphthyl phosphoric acid more active part of the two antipodes isolated.
  • the starting materials are known or, if they are new, can be obtained by methods known per se.
  • the compounds according to the invention can be used themselves or as part of a pharmaceutical preparation, as a single active ingredient in combination with one another or with known cardiovascular or vascular therapeutics, for example ACE inhibitors, antiatherosclerotic agents, antihypertensives, beta-blockers, cholesterol-lowering agents, diuretics, calcium channel blockers, coronary dilatants, coronary dilatants Vasodilators, phosphodiesterase inhibitors, in particular - (V) -, or platelet aggregation inhibitors or other substances, also used as cardiovascular therapeutics, combined, can be used for their clinical use
  • ACE inhibitors antiatherosclerotic agents, antihypertensives, beta-blockers, cholesterol-lowering agents, diuretics, calcium channel blockers, coronary dilatants, coronary dilatants Vasodilators, phosphodiesterase inhibitors, in particular - (V) -, or platelet aggregation inhibitors or other substances, also used as cardiovascular therapeutics, combined, can be used for their clinical
  • the respective pharmaceutical preparation is preferably provided in liquid or solid form.
  • Solutions are suitable for this, in particular for the preparation of drops, injections or aerosol sprays, furthermore suspensions, emulsions, syrups, tablets, film tablets, dragees, capsules, Pellets, powders, lozenges, implants, supposito ⁇ en, creams, gels, ointments, plasters or other transdermal systems
  • the pharmaceutical preparations contain customary galenically usable, organic or inorganic carriers d Auxiliary substances, which should themselves be chemically indifferent to the respective active substances.
  • the chemical devatization during application to carrier materials is also included, this relates in particular to the formation of adducts with sugar derivatives such as croscarmeloses or cyclodextiles.
  • Suitable pharmaceutical auxiliary substances are, without being restricted to this, water , Salt solutions, alcohols, vegetable oils, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, highly disperse silicon dioxide, paraffin, fatty acid mono- and diglycides, cellulose derivatives, polyvinylpyrrolidone and the like.
  • the preparation can be sterilized and, if necessary, with auxiliary agents such as lubricants, fillers, fillers -, mold release agents, lubricants, disintegrants, moisturizers, adsorbents or counter-explosives, preservatives, stabilizers, emulsifiers, solubilizers, salts for influencing the osmotic pressure, buffer solutions, coloring, fragrance, aroma or sweet
  • auxiliary agents such as lubricants, fillers, fillers -, mold release agents, lubricants, disintegrants, moisturizers, adsorbents or counter-explosives, preservatives, stabilizers, emulsifiers, solubilizers, salts for influencing the osmotic pressure, buffer solutions, coloring, fragrance, aroma or sweet
  • auxiliary agents such as lubricants, fillers, fillers -, mold release agents, lubricants, disintegrants, moisturizers, adsorbents or counter-explosives, preserv
  • the compounds according to the invention surprisingly have the desired properties.
  • they are distinguished, in part, by an optimized NO transfer, for example by their differentiated content of reductively biotransforming NO precursor groups or by an improved multiphase NO liberation and depending on the intended use increased lipophysis or hydrophilicity as well as by pharmacodynamic Reduction in preload, reduced increase in endothelin in plasma, pronounced inhibition of platelet aggregation by platelet-active groups and, even in a subhemodynamic dose, by endothelium-protective action.
  • the fact that the compounds according to the invention are notable for good penetration of physiological membranes is particularly advantageous.
  • the compounds used according to the invention show surprisingly high vasodilating properties with improved bioavailability and increased hydrophilicity as well as easier biotransformation in functional tests on isolated blood vessels (rabbit aorta) to end metabolism, these end metabolites generally well tolerated or ubiquitous Pure body-own compounds They are characterized as surprisingly strong hydrophilic nitrate vasodilators, which have a longer half-life and improved bioavailability compared to lipophilic nitrates.
  • PETN pentaerythryl tetranitrate
  • the combined aqueous extracts A were extracted three times with ether, and from the separated from the aqueous layer B ether layer after drying flashed over anhydrous Na 2 S0 4, the ether
  • the very viscous, oily Eindampfruckstand was as crude Pentaeryth ⁇ tyldinitrat (PEDN) identifies
  • the heßnge portion B which, in addition to the pentaerythritol mononitrate (PEMN) and pentaerythritol denitration products, mainly hydrazine nitrate, was acidified with 2N-H 2 SO "until the gas evolution ceased (N 2 , N 2 O t NO N 3 H), then at 20 mm Hg to incipient separation of solid products concentrated and extracted with ether, the remaining after evaporation of the ether crystalline substance from F p 62 ° C was used as crude PEMN identified after washing with cold chloroform and Umk ⁇ stallisation from chloroform showed
  • the PETnN was also processed in such a way that after washing with water it was stirred with 100 ml of water and then left at a temperature not higher than 20 ° C. until the next day. It gave stable, colorless crystals of F p 32 ° in air C, where 2.15% water was determined with Karl-Fischer reagent 2.14 + 0.05% of water and by vacuum drying at 60 ° C, corresponding to a hydrate of composition C 5 H 9 O 3 N 10 1/3 of H 2 0
  • PETnN is represented by nitration of pentaerythritol with HN0 3 (95% ⁇ g) in the presence of urea.
  • PEDN and PEMN are prepared from PETnN by hydrazinolysis (4 mol NH 2 NH 2 (50% ⁇ g)) with subsequent column chromatography separation of the 1 1 mixture
  • Example 10 0 001 mol of bis-MS is esterified azeotropically with 0.0011 mol of 4-butyl-3-hydroxy-1, 2,4-oxad ⁇ azol-5-one in the presence of benzene and catalytic amounts of H 2 S0 (yield 60%)
  • T ⁇ -PSCI oily 3-n ⁇ tryloxy-2,2-b ⁇ s (n ⁇ tryloxymethyl) propionic acid chloride
  • the acid chlorides of the compounds 2,2-b ⁇ s (n ⁇ tryloxymethyl) malonic acid (bis-MS) and 2-carboxy-2-n ⁇ tryloxymethylmalonic acid (CN-MS) are obtained analogously to the representation of 2,2-b ⁇ s (n ⁇ tryloxymethyl) malonic acid idchloride (bis-MSCl ) is twice the amount of thionyl chloride and 3-times of 2-chlorocarbonyl-2-n ⁇ tryloxymethyl-malonklad (CN-MSCI)
  • Amount of thionyl chloride uses 70% or 45% yield
  • T ⁇ -PS 1 g (3.5 mmol) of T ⁇ -PS is mixed with 10.5 mmol of ethanol, 20 mg of toluenesulfonic acid and 30 ml of chloroform and heated under reflux for 12 hours on a water separator
  • esters of the carboxylic acid Bis-MS and CN-MS are obtained analogously by doubling (in the case of Bis-MS) or tripling (in the case of CN-MS) the added reagents
  • reaction mixture is gasified for a further 120 mm at -5 ° C. and then poured into ice water.
  • the aqueous phase is etherified twice, the organic phase is washed with 10% hydrogen carbonate solution and with water, dried over sodium sulfate and the solvent is evaporated in vacuo.
  • CDCI 3 corresponds to 13 C-NMR (75 MHz, CDCI 3 )
  • Example 17 3.4 mmol of L-carnitine hydrochloride are esterified with 1 g (3.4 mmol) of T ⁇ -PSCI dissolved in 25 ml of dioxane. After 30 mm, the mixture is poured into 100 ml of ice water and weakly acidified with dilute hydrochloric acid. The oily product is subjected to column chromatography purified yield 40%
  • the antiplatelet and antiplatelet activity of the compounds is determined by the method of Rehse et al (Arch Pharm 324, 301-305 (1991), Arch Pharm. Pharm. Med. Chem. 329, 535 (1996)), which is established as a model for describing anticoagulant and antithrombotic properties.
  • vasodilating properties were investigated in experiments on isolated aortic rings of the rabbit (Hüsgen, Noack, Kojda: Int Co ⁇ fer. "Mediators in the cardiovascular System", p. 9, Malta 2.-5.6J 994) by hanging them in organ baths and stimulated by vasoconstrictors such as phenylephrine. After establishing a stable smooth muscular tone, the influence of the tone on cumulative concentration-effect curves is determined by adding the above vasodilators. For this purpose, the organ bath buffer is mixed with increasing concentrations between 1nM and 10 ⁇ M of the vasodilator, whereby between the different fractions is not washed out.
  • bMaximum effective concentration EC50 reflects the potency and can be recorded as a pD2 value (concentration in logM).
  • One tablet has the composition:
  • Active substance / s a) compound according to example 10 20 mg b) compound according to example 10 50 mg c) compound according to example 10 80 mg d) compound according to example 11 20 mg e) compound according to example 11 50 mg f) compound according to example 11 80 mg g) compound according to Example 12 20 mg h) compound according to Example 12 50 mg i) compound according to Example 12 80 mg j) compound according to Example 14 20 mg k) compound according to Example 14 50 mg I) compound according to Example 14 80 mg m) compound according to Example 15 20 mg n) compound according to Example 15 50 mg o) compound according to Example 15 80 mg p) compound according to Example 17 50 mg q) Compound according to Example 7 30 mg

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Saccharide Compounds (AREA)
EP98936180A 1997-06-11 1998-06-11 Neue pentaerythritderivate, deren herstellung und verwendung sowie intermediate zur synthese derselben Withdrawn EP0988282A2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19725340 1997-06-11
DE19725340 1997-06-11
PCT/DE1998/001635 WO1998056759A2 (de) 1997-06-11 1998-06-11 Neue pentaerythritderivate, deren herstellung und verwendung sowie intermediate zur synthese derselben

Publications (1)

Publication Number Publication Date
EP0988282A2 true EP0988282A2 (de) 2000-03-29

Family

ID=7832585

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98936180A Withdrawn EP0988282A2 (de) 1997-06-11 1998-06-11 Neue pentaerythritderivate, deren herstellung und verwendung sowie intermediate zur synthese derselben

Country Status (20)

Country Link
US (1) US6365611B1 (ru)
EP (1) EP0988282A2 (ru)
JP (1) JP2002504903A (ru)
CN (1) CN1266429A (ru)
AU (1) AU8532198A (ru)
BG (1) BG104021A (ru)
CA (1) CA2293407A1 (ru)
DE (2) DE19826781A1 (ru)
EA (1) EA200000006A1 (ru)
EE (1) EE9900568A (ru)
HR (1) HRP980313A2 (ru)
HU (1) HUP0002925A3 (ru)
IL (1) IL133410A0 (ru)
NO (1) NO996128D0 (ru)
NZ (1) NZ501414A (ru)
PL (1) PL337775A1 (ru)
SK (1) SK169599A3 (ru)
TR (2) TR199903054T2 (ru)
WO (1) WO1998056759A2 (ru)
ZA (1) ZA985064B (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1306184B1 (it) 1999-08-05 2001-05-30 Sigma Tau Ind Farmaceuti Nitrilossi derivati della (r) e (s)-carnitina.
DE19950483A1 (de) * 1999-10-19 2001-05-10 Isis Pharma Gmbh Verfahren zur Herstellung von 3-Nitryloxy-2,2-bis(nitryloxymethyl)-propanal
US20040013649A1 (en) * 2002-05-10 2004-01-22 Inex Pharmaceuticals Corporation Cancer vaccines and methods of using the same
US20040009944A1 (en) * 2002-05-10 2004-01-15 Inex Pharmaceuticals Corporation Methylated immunostimulatory oligonucleotides and methods of using the same
CA2542099A1 (en) * 2003-10-11 2005-04-21 Inex Pharmaceuticals Corporation Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3419571A (en) * 1966-04-06 1968-12-31 Warner Lambert Pharmaceutical Method for relieving coronary insufficiency
DE3836021A1 (de) * 1988-10-22 1990-05-03 Boehringer Mannheim Gmbh Arzneimittel enthaltend nitroxyalkylamine mit amidfunktion und verfahren zur herstellung dieser verbindungen
DE19515970A1 (de) 1995-05-02 1996-11-07 Bayer Ag Acetylsalicylsäurenitrate
CA2267129A1 (en) * 1996-10-10 1998-04-16 Isis Pharma Gmbh New pentaerythritol derivatives, their production and use and intermediates for their synthesis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9856759A2 *

Also Published As

Publication number Publication date
TR199903054T2 (xx) 2000-07-21
HUP0002925A2 (hu) 2001-07-30
HUP0002925A3 (en) 2002-11-28
DE19826781A1 (de) 1998-12-17
EA200000006A1 (ru) 2000-08-28
JP2002504903A (ja) 2002-02-12
BG104021A (bg) 2000-07-31
ZA985064B (en) 1998-08-28
NZ501414A (en) 2001-12-21
NO996128L (no) 1999-12-10
IL133410A0 (en) 2001-04-30
SK169599A3 (en) 2000-11-07
HRP980313A2 (en) 1999-04-30
AU8532198A (en) 1998-12-30
CA2293407A1 (en) 1998-12-17
NO996128D0 (no) 1999-12-10
WO1998056759A2 (de) 1998-12-17
EE9900568A (et) 2000-08-15
CN1266429A (zh) 2000-09-13
US6365611B1 (en) 2002-04-02
PL337775A1 (en) 2000-09-11
TR200003352T2 (tr) 2001-02-21
DE19880813D2 (de) 2000-05-31
WO1998056759A3 (de) 1999-09-16

Similar Documents

Publication Publication Date Title
DE2445584C3 (de) L- bzw. DL-2-Methyl-3- (3', 4'-dihydroxyphenyl)-alanin-ester, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE69711411T2 (de) Verwendung von gamma-hydroxybuttersäureamiden in der behandlung von drogenabhängigkeit und insbesondere von alcoholismus
DE2434911A1 (de) Phenylaethylamin-derivate
DD145265A5 (de) Verfahren zur herstellung von phenethanolaminen
DE2439859A1 (de) Verfahren zur herstellung von 3-(3,4dihydroxy-phenyl)-serin
WO1998056759A2 (de) Neue pentaerythritderivate, deren herstellung und verwendung sowie intermediate zur synthese derselben
DE3314878C2 (ru)
DE2743166A1 (de) 2-(3-phenyl-2-amino-propionyloxy)- essigsaeurederivate, verfahren zu ihrer herstellung und sie enthaltende arzneimittel
WO1998015521A1 (de) Neue derivate des pentaerythrits, deren herstellung und verwendung sowie intermediate zur synthese derselben
DE2656088A1 (de) Neues benzylalkoholderivat und verfahren zu seiner herstellung
DE19830006A1 (de) Pentaerythritolderivate und Intermediate zu deren Herstellung
DE3873696T2 (de) Derivate des cysteins, verfahren zur herstellung und verwendung davon.
DE19726812A1 (de) Neue Derivate des Pentaerythrits, deren Herstellung und Verwendung sowie Intermediate zur Synthese derselben
DE19641667A1 (de) Neue Ester der Salpetersäure sowie deren Herstellung und Verwendung
DE1795003C3 (de) 4H-13-Benzoxazin-2-on-3-acetohydroxamsäure, Verfahren zu deren Herstellung und Arzneimittel
DE2004301A1 (de) Phenylserinderivate
DE19827981A1 (de) Analytische Substrate
DE19652345A1 (de) Neue Salpetersäureester, deren Herstellung und Verwendung
DE3323077A1 (de) Racemische und optisch aktive eburnan-oxim-ether, verfahren zu deren herstellung und pharmazeutische praeparate, welche diese enthalten
DE2615129B2 (de) Tripeptide, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zubereitungen
CH635314A5 (de) Verfahren zur herstellung von 2-(phenylalkylhydrazono)-propionsaeurederivaten.
WO1999067430A2 (de) Analytische substrate und antioxidative mittel
DE1620172C (de) Optisch aktives oder racemisches 2,3-Dimethoxy-10-aminoberbin, dessen Salze und Verfahren zur Herstellung dieser Verbindung
AT371101B (de) Verfahren zur herstellung neuer optisch aktiver phenethanolamine und der pharmazeutisch unbedenklichen salze hiervon
AT332381B (de) Verfahren zur herstellung von neuen l-alfa-hydrazino-beta-phenylpropionsauren und ihren salzen

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19991208

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 19991208;LT PAYMENT 19991208;LV PAYMENT 19991208;MK PAYMENT 19991208;RO PAYMENT 19991208;SI PAYMENT 19991208

17Q First examination report despatched

Effective date: 20010709

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 20020321